Search results
Showing 256 to 270 of 666 results for kidney or kidneys or renal
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]
Awaiting development Reference number: GID-TA11111 Expected publication date: TBC
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement.
View quality statements for QS36Show all sections
Sections for QS36
- Quality statements
- Quality statement 1: Presentation with unexplained fever of 38°C or higher
- Quality statement 2: History and examination – recording of risk factors
- Quality statement 3: Laboratory reporting – differentiation of E. coli and non-E. coli organisms
- Quality statement 4: Information about recognising re-infection
- Update information
- About this quality standard
effectiveness of 6-monthly imaging for 3 years for people with recurrent calcium renal or ureteric stones? Any explanatory notes(if...
Urinary tract infection (lower): antimicrobial prescribing (NG109)
This guideline sets out an antimicrobial prescribing strategy for lower urinary tract infection (also called cystitis) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)
NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .
We have moved interventional procedures guidance 609 to become HealthTech guidance 468. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72
Awaiting development Reference number: GID-TA11751 Expected publication date: TBC
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.
NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Awaiting development Reference number: GID-TA11670 Expected publication date: TBC
SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)
Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.